ISPOR Baltimore 2018 Posters
ISPOR Baltimore 2018 Posters
Reimagining evidence generation across the spectrum of healthcare
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBS
Our 37 poster contributions at ISPOR demonstrate how we are putting science behind new and flexible study designs to address key research questions and specific therapy area challenges, enabling better healthcare decisions globally.
Check back on this page throughout the ISPOR Baltimore 2018 event as we'll be adding new posters after they've been presented.
Monday, May 21
- A COST-EFFECTIVENESS ANALYSIS OF A FIRST-IN-CLASS, TRIPLE FIXED DOSE COMBINATION THERAPY AGAINST LABA/LAMA THERAPY IN MODERATE-SEVERE COPD
- A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS) COMPARING TERIPARATIDE TO ALENDRONATE FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- A REVIEW OF NICE TECHNOLOGY APPRAISALS IN ONCOLOGY USING SINGLE ARM TRIALS (SAT) EVIDENCE
- ACCESSING NEWLY IMPLEMENTED CLAIMS DATABASES IN SOUTHEAST-ASIA: ADVANCING HEALTH RESEARCH
- ANALYZING PRESCRIPTION DATA TO TARGET HARD-TO-IDENTIFY PATIENT POPULATIONS FOR CLINICAL TRIALS: A CASE STUDY IN NARCOLEPSY
- ASSESSING THE BENEFITS OF CO-PAY CARD USAGE AMONG DIABETIC PATIENTS IN CANADA
- CONVERSION OF HYPOGLYCEMIA UTILITY DECREMENTS FROM CATEGORICAL UNITS REFLECTING EVENT HISTORY INTO EVENT SPECIFIC DISUTILITY SCORES APPLICABLE TO DIABETES DECISION MODELS
- DELPHI METHOD: A QUALITATIVE APPROACH FOR QUANTITATIVE RESULTS
- EVIDENCE-BASED VALUATION: A NOVEL FRAMEWORK FOR DRUG PRICING
- HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH PERSISTENT ASTHMA BY ATTAINMENT OF HEALTHCARE EFFECTIVENESS AND DATA INFORMATION SET (HEDIS) MEASURES
- HEALTHCARE RESOURCES PATTERNS AND COST ANALYSIS OF PULMONARY ARTERIAL HYPERTENSION IN A TERTIARY CARE SETTING IN MEXICO CITY
- HISTORY OF LIPID LOWERING THERAPY AND CARDIOVASCULAR MEDICATION USE AMONG PATIENTS INITIATING PCSK9 INHIBITORS IN THE UNITED STATES
- INCREMENTAL HEALTHCARE RESOURCE USE AND COSTS ASSOCIATED WITH SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS
- INPATIENT COST OF ACUTE CARE FOR SEVERE BURN PATIENTS: VALIDATION OF ECONOMIC MODEL FOR ADULTS AND CHILDREN
- LEVERAGING CLINICAL FIELDS FROM A US EMR DATABASE TO IDENTIFY AND CHARACTERIZE LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) IN REAL WORLD PRACTICE SETTINGS
- MEASURING TREATMENT SATISFACTION WITH MEDICATION FROM PATIENTS’ PERSPECTIVE: CONCEPTUAL MODELS AND A REVIEW OF MEASURES
- REVIEW AND VALIDATION OF CARDIOVASCULAR RISK PREDICTION MODELS IN EAST ASIAN POPULATIONS
Tuesday, May 22
- ANTI-VEGF DOSING INTERVALS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A RETROSPECTIVE COHORT STUDY IN AUSTRALIA
- ASSESSING THE COST-EFFECTIVENESS OF THREE-MONTHLY PALIPERIDONE PALMITATE VERSUS ITS PRIOR MONTHLY FORMULATION FOR THE MANAGEMENT OF SCHIZOPHRENIA IN THE UK SETTING
- BILATERAL TREATMENT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A RETROSPECTIVE COHORT STUDY IN THE US
- CHANGES IN HEALTHCARE RESOURCE USE AND COSTS ASSOCIATED WITH THE USE OF ADJUNCTIVE ATYPICAL ANTIPSYCHOTICS IN MAJOR DEPRESSIVE DISORDER
- COST-EFFECTIVENESS ANALYSIS OF AMISULPRIDE AND OLANZAPINE FOR PATIENTS WITH SCHIZOPHRENIA IN CHINA
- COST-EFFECTIVESS ANALYSIS OF BRODALUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
- COST-EFFECTIVENESS OF TREATING OVERACTIVE BLADDER WITH MIRABEGRON VERSUS ANTIMUSCARINICS IN MEXICO
- EFFICACY OF BRODALUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: A NETWORK META-ANALYSIS
- HEPATOCELLULAR CARCINOMA IN THE BRAZILIAN PUBLIC HEALTH SYSTEM: A BURDEN OF ILLNESS MODEL
- MEDI-APEX: A RETROSPECTIVE NON-INTERVENTIONAL STUDY OF PD-L1 PREVALENCE AND CLINICAL OUTCOMES FOR NON-SMALL CELL LUNG CANCER (NSCLC) IN ASIA-PACIFIC
- ONLINE METHODS FOR THE ELECTRONIC VALIDATION OF THE TREATMENT SATISFACTION FOR MEDICATION QUESTIONNAIRE
- POTENTIAL IMPACT OF CHANGES TO BASKET OF COMPARATOR COUNTRIES FROM PMPRB7 TO PMPRB12 ON CANADIAN PRODUCT LIST PRICES
- REDUCTION IN HOSPITALIZATIONS AND MEDICAL COST SAVINGS ASSOCIATED WITH EARLY USE OF ADJUNCTIVE ATYPICAL ANTIPSYCHOTICS IN MAJOR DEPRESSIVE DISORDER
- REAL-WORLD TREATMENT PATTERNS FOR PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TREATED WITH IMMUNO-ONCOLOGY (IO) THERAPY
- RELATIONSHIP BETWEEN PATIENT CHARACTERISTICS AND LENGTH OF STAY FOR SEVERE BURN PATIENTS: ANALYSIS OF THE AMERICAN BURN ASSOCIATION NATIONAL BURN REPOSITORY
- SYMPTOMS AND IMPACTS IN ADVANCED/METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: FINDINGS FROM QUALITATIVE PATIENT INTERVIEWS
- TREATMENT PATTERNS AND ECONOMIC BURDEN OF CHINESE METASTATIC COLORECTAL CANCER PATIENTS: A RETROSPECTIVE STUDY OF ELECTRONIC MEDICAL RECORDS FROM URBAN CHINA
- VALIDITY OF PATIENT-REPORTED OUTCOMES FROM COLUMBUS, A RANDOMIZED OPEN LABEL PHASE III CLINICAL TRIAL OF ENCORAFENIB PLUS BINIMETINIB VS VEMURAFENIB IN ADVANCED BRAF-MUTANT MELANOMA
Wednesday, May 23
- DEVELOPMENT OF A PATIENT-REPORTED OUTCOME (PRO) INSTRUMENT FOR PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
- REAL-WORLD CLINICAL EFFECTIVENESS OF LIRAGLUTIDE 3.0 MG FOR WEIGHT MANAGEMENT IN CANADA